Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats
PBN-AR
Instytucja
Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk
Informacje podstawowe
Główny język publikacji
en
Czasopismo
CLINICAL AND EXPERIMENTAL HYPERTENSION (20pkt w roku publikacji)
ISSN
1064-1963
EISSN
Wydawca
INFORMA HEALTHCARE
DOI
URL
Rok publikacji
2017
Numer zeszytu
2
Strony od-do
183-195
Numer tomu
39
Identyfikator DOI
Liczba arkuszy
1.44
Słowa kluczowe
en
Chronic kidney disease
endothelin system
hypertension
renin-angiotensin system
5/6 nephrectomy
Streszczenia
Język
en
Treść
Background: Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin-angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). In this study, we examined if additional protection is provided when ETA blockade is applied in rats with already developed CKD. Methods: For complex RAS inhibition, an angiotensinconverting enzyme inhibitor along with angiotensin II type 1 receptor blocker was used. Alternatively, ETA receptor blocker was added to the RAS blockade. The treatments were initiated 6 weeks after 5/6 NX and the follow-up period was 50 weeks. Results: When applied in established CKD, addition of ETA receptor blockade to the complex RAS blockade brought no further improvement of the survival rate (30\% in both groups); surprisingly, aggravated albuminuria (588 +/- 47 vs. 245 +/- 38 mg/24 h, p < 0.05) did not reduce renal glomerular injury index (1.25 +/- 0.29 vs. 1.44 +/- 0.26), did not prevent the decrease in creatinine clearance (203 +/- 21 vs. 253 +/- 17 mu l/min/100 g body weight), and did not attenuate cardiac hypertrophy to a greater extent than observed in 5/6 NX TGR treated with complex RAS blockade alone. Conclusions: When applied in the advanced phase of CKD, addition of ETA receptor blockade to the complex RAS blockade brings no further beneficial renoprotective effects on the CKD progression in 5/6 NX TGR, in addition to those seen with RAS blockade alone.
Cechy publikacji
discipline:Biologia medyczna
discipline:Medycyna
discipline:Nauki farmaceutyczne
discipline:Medical biology
discipline:Medicine
discipline:Pharmacy
Original article
Original article presents the results of original research or experiment.
Oryginalny artykuł naukowy
Oryginalny artykuł naukowy przedstawia rezultaty oryginalnych badań naukowych lub eksperymentu.
Inne
System-identifier
PBN-R:818107
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych